Switch from intravenous to subcutaneous abatacept: Our experience

被引：0
|
作者：
Carlos Nieto-Gonzalez, Juan [1 ]
Ovalles-Bonilla, Juan G. [1 ]
Estrada, Eduardo [2 ]
Monteagudo, Indalecio [1 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Serv Reumatol, Madrid, Spain
[2] Univ Camilo Jose Cela, Dept Psicol, Madrid, Spain
来源：
REUMATOLOGIA CLINICA | 2020年 / 16卷 / 02期
关键词：
EFFICACY;
D O I：
10.1016/j.reuma.2018.02.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：187 / 188
页数：2
相关论文
共 50 条
  • [1] FAILURE OF THE SWITCH FROM THE INTRAVENOUS TO THE SUBCUTANEOUS FORMULATION OF ABATACEPT DUE TO A DISEASE REACTIVATION: OUR EXPERIENCE
    Reggia, R.
    Cavazzana, I.
    Tincani, A.
    Franceschini, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 732 - 732
  • [2] REAL CLINICAL EXPERIENCE WITH ABATACEPT, FROM INTRAVENOUS TO SUBCUTANEOUS
    Nieto-Gonzalez, J. C.
    Janta, I.
    Ovalles-Bonilla, J. G.
    Serrano, B.
    Mata, C.
    Gonzalez-Benitez, R.
    Valor, L.
    Lopez-Longo, F. J.
    Gonzalez-Fernandez, C. M.
    Monteagudo, I.
    Naredo, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1024 - 1024
  • [3] Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
    Keystone, Edward Clark
    Kremer, Joel M.
    Russell, Anthony
    Box, Jane
    Abud-Mendoza, Carlos
    Garza Elizondo, Mario
    Luo, Allison
    Aranda, Richard
    Delaet, Ingrid
    Swanink, Rene
    Gujrathi, Sheila
    Luggen, Michael
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (06) : 857 - 861
  • [4] Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety
    Reggia, Rossella
    Franceschini, Franco
    Tincani, Angela
    Cavazzana, Ilaria
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (02) : 193 - 195
  • [5] SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP AND MMN: FRENCH EXPERIENCE ON 28 PATIENTS
    Cauquil, C.
    Viala, K.
    Le Masson, G.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 166 - 166
  • [6] Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study
    Desplats, Marie
    Pascart, Tristan
    Jelin, Germain
    Norberciak, Laurene
    Philippe, Peggy
    Houvenagel, Eric
    Goeb, Vincent
    Flipo, Rene-Marc
    CLINICAL RHEUMATOLOGY, 2017, 36 (06) : 1395 - 1400
  • [7] Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study
    Marie Desplats
    Tristan Pascart
    Germain Jelin
    Laurène Norberciak
    Peggy Philippe
    Eric Houvenagel
    Vincent Goeb
    René-Marc Flipo
    Clinical Rheumatology, 2017, 36 : 1395 - 1400
  • [8] "I Want to Switch Back": Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
    Gupta, Rishi
    Shipa, Muhammad
    Yeoh, Su-Ann
    Buck, Pauline
    Ehrenstein, Michael
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [9] SUBCUTANEOUS ABATACEPT VERSUS INTRAVENOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: LONG-TERM DATA FROM THE ACQUIRE TRIAL
    Genovese, Mark C.
    Covarrubias Cobos, Arturo
    Leon, Gustavo
    Mysler, Eduardo F.
    Keiserman, Mauro W.
    Valente, Robert M.
    Nash, Peter T.
    Simon Campos, J. Abraham
    Porawska, Wieslawa
    Box, Jane H.
    Legerton, Clarence W., III
    Nasonov, Evgeny L.
    Durez, Patrick
    Pappu, Ramesh
    Delaet, Ingrid
    Teng, Julie
    Alten, Rieke
    RHEUMATOLOGY, 2012, 51 : 128 - 129
  • [10] SWITCHING INTRAVENOUS ABATACEPT AND TOCILIZUMAB TO SUBCUTANEOUS INJECTIONS DURING THE COVID-19 PANDEMIC: A FRENCH EXPERIENCE
    Combier, A.
    Wanono, S.
    Poiroux, L.
    Frantz, C.
    Descamps, E.
    Fogel, O.
    Boisson, M.
    Ayral, X.
    Bottois, C.
    Allanore, Y.
    Avouac, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1364 - 1365
12345